Top Markets
#1 MowCat MowCat +368.91%
#2 龙虾 (Lobster) 龙虾 (Lobster) +67.78%
#3 SODAX SODAX +51.82%
#4 Cortex Cortex +32.58%
#5 MarsCoin MarsCoin +23.54%
#6 DexNet DexNet +23.19%
#7 OpenEden OpenEden +20.03%
#8 Magma Finance Magma Finance +17.47%
#9 wojak wojak +16.12%
#10 Akedo Akedo +15.73%
Coin of the day
MowCat MowCat
설정
언어
한국어
통화
USD
테마
Biotest AG Biotest AG

Biotest AG

BIO
주식 순위 #7311
Biotest AG is a German biopharmaceutical company focused on the global... Biotest AG is a German biopharmaceutical company focused on the global development, manufacturing, and commercialization of biological medications. The firm organizes its activities into the Therapy, Plasma & Services, and Other segments. Its product portfolio addresses critical needs in hematology, clinical immunology, and intensive care medicine. Among its offerings are treatments for hemophilia A (such as Haemoctin and Vihuma) and hemophilia B (like Haemonine), covering both acute care and prevention. Biotest also provides therapies for various viral infections, including cytomegalovirus (Cytotect CP), hepatitis B (Fovepta, Hepatect, Zutectra), and varicella zoster (Varitect). Additionally, its products, such as Intratect and IgG Next Generation, are utilized for primary and secondary immune deficiencies, autoimmune disorders, and certain neurological conditions. The company further supplies solutions to manage circulating blood volume (Albiomin, Biseko), address clotting factor deficiencies (Cofact, Fibrinogen), and combat serious infections like community-acquired pneumonia and COVID-19 (Trimodulin), as well as general bacterial infections (Pentaglobin). Established in 1946 as Biotest Serum-Institut GmbH, the company adopted its current name, Biotest Aktiengesellschaft, in 1986. Headquartered in Dreieich, Germany, Biotest Aktiengesellschaft has been operating as a subsidiary of Grifols, S.A. since January 21, 2022.
주가
$47.45
마지막 동기화: 2026-05-13
시가총액
$1.63B
변동 (1일)
2.04%
변동 (1년)
3.15%
국가
DE
거래 Biotest AG (BIO)

카테고리

Healthcare
Biotest AG (BIO)의 매출
Aug 2026 기준 매출 TTM: 0
Biotest AG의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 0 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Biotest AG의 수익 기록 (2026 ~ 2026)
매년 말 매출
연도 매출 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH